

# Endometrial tissue ablation: a clinical trial

<b>Submission date</b> 12/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 27/10/2010	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr J. Kleijn

**Contact details**  
Maxima Medisch Centrum  
Locatie Veldhoven  
P.O. Box 7777  
Veldhoven  
Netherlands  
5500 MB  
+31 (0)40 8888000  
J.Kleijn@mmc.nl

## Additional identifiers

## Study information

**Scientific Title**

### Study objectives

Demonstrate that the HydroThermAblation procedure is equally effective compared to the Novasure procedure in achieving patient satisfaction at twelve months post-treatment for menorrhagia secondary to DUB.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Dysfunctional uterine bleeding

**Interventions**

Hydrothermablator (HTA) System versus ablation with Novasure

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Patients satisfaction:

At each follow up visit/telephone call patients satisfaction was noted. Patients can express their level satisfaction by using - completely satisfied, satisfied, doubtful satisfied or not satisfied. It is also noted if any kind of reintervention is performed, such as the use of oral contraceptives or surgery.

**Key secondary outcome(s)**

1. Quality of life: all patients are asked to complete quality of life questionnaires at baseline, at two days, six weeks, three months, six months and twelve months after surgery. We evaluate quality of life with the medical outcomes study SF 36, the Rotterdam symptom checklist and a structured clinical history questionnaire.
2. Amenorrhoea: at each follow up visit/ telephone call duration of menstruation, dysmenorrhoea and presence of clots are registered. Patients also complete a pictorial chart.

**Completion date**

01/08/2007

**Eligibility****Key inclusion criteria**

1. Refractory menorrhagia with no definable organic cause (dysfunctional uterine bleeding).
2. Age over 25 years old

3. Uterine sound measurement of 6.0 - 12 cm (external os to internal fundus).
4. Failed, contraindicated or intolerance to conservative (medical) therapy.
5. Menstrual Diary:  
A minimum PBLAC score of > 150 for 1 month. Intracavitary pathology, such as type 2 fibromas and small polyps ( $\leq 2$ cm), confirmed by hysteroscopy or Saline Infused Sonography (SIS)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Not Specified

**Key exclusion criteria**

1. Presence of bacteremia, sepsis, or other active systemic infection
2. Active or recurrent chronic pelvic inflammatory disease
3. Patients with documented coagulopathies
4. Symptomatic endometriosis
5. Prior uterine surgery (except low segment cesarean section) which interrupts the integrity of the uterine wall e.g.transmural myomectomy or classical cesarean section. Prior endometrial ablations.
6. Patients on medications that could thin the myometrial muscle, such as long-term steroid use.
7. Patients on anticoagulants.
8. Desire to have children or to preserve fertility
9. Patients currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation.
10. Abnormal/Obstructed Cavity as confirmed by hysteroscopy, Saline Infused Sonography (SIS) or HSG. Specifically: Septate or bicornuate uterus or other congenital malformation of the uterine cavity.

**Date of first enrolment**

01/03/2005

**Date of final enrolment**

01/08/2007

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

Maxima Medisch Centrum  
Veldhoven

Netherlands  
5500 MB

## Sponsor information

### Organisation

Maxima Medisch Centrum (The Netherlands)

### ROR

<https://ror.org/02x6rcb77>

## Funder(s)

### Funder type

Hospital/treatment centre

### Funder Name

Máxima Medisch Centrum (Netherlands)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2010		Yes	No